HLX301 is a bispecific antibody to PD-L1 and TIGIT being evaluated in a Phase I study for advanced solid tumors and lymphomas (NCT05390528), while HLX53 is an anti-TIGIT Fc fusion protein also being investigated in solid tumors and lymphomas. Here, TIGIT is linked to lymphoma.